Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × pCR Rate × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 77 Prostatic Neoplasms 55 Breast Neoplasms 49 Lung Neoplasms 31 Neoplasms 20 Neoplasm Metastasis 18 Stomach Neoplasms 14 Head and Neck Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 12 Recurrence 7 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Adenocarcinoma of Lung 7 Sarcoma 6 Esophageal Neoplasms 6 Carcinoma, Transitional Cell 5 Carcinoma, Squamous Cell 5 Urinary Bladder Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Triple Negative Breast Neoplasms 3 Advanced Non-Small Cell Lung Cancer 3 Adenocarcinoma, Bronchiolo-Alveolar 3 Solid Tumor 2 Small Cell Lung Carcinoma 2 Prostatic Neoplasms, Castration-Resistant 2 Inflammatory Breast Neoplasms 2 Hormone Refractory Prostate Cancer 2 HER2-positive Breast Cancer 2 Fallopian Tube Neoplasms 2

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡